Cefuroxime – Indications and Patent Overview
| Aspect | Details |
|------------|-------------|
| Drug class | Second‑generation cephalosporin antibiotic |
| Formulations | Oral (cefuroxime axetil), intravenous (cefuroxime sodium) |
| Key indications | • Acute bacterial sinusitis
• Acute otitis media (middle‑ear infection)
• Community‑acquired pneumonia (CAP) in adults
• Bacterial pharyngitis (including streptococcal pharyngitis)
• Mild‑to‑moderate urinary tract infections (UTIs)
• Skin and soft‑tissue infections (e.g., cellulitis)
• Dental abscesses (often as part of a dental regimen) |
| Common bacterial spectrum | Penicillin‑sensitive Streptococcus spp., Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus (methicillin‑sensitive), Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli (some strains), Proteus mirabilis, Enterobacter spp. (some strains) |
| Mechanism of action | Inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins (PBPs), especially PBP2 and PBP3; this disrupts peptidoglycan cross‑linking, leading to cell lysis. |
| Pharmacokinetics (oral) | • Bioavailability ~ 65 % (axetil prodrug)
• Peak plasma concentration (Cmax) ~ 0.5 µg/mL within 1–2 h
• Half‑life ~ 1 h (IV), 1–2 h (oral)
• Renally excreted; dose adjustment needed in renal impairment |
---
Patent Landscape
| Patent | Owner / Filing Country | Scope | Status (as of 2024) |
|------------|---------------------------|-----------|--------------------------|
| US 4,134,562 (Cefuroxime) | Merck & Co. (original developer) | Novel β‑lactam core structure; synthetic route | Expired (first‑publication 1978 → expiry 2005) |
| US 4,381,480 (Cefuroxime Axetil) | Merck & Co. | Oral pro‑drug formulation (axetil ester) | Expired (published 1982 → expiry 2002) |
| WO 1995/014945 (Cefuroxime and novel salt forms) | Merck & Co. | New salt forms and improved solubility | Expired (published 1995 → expiry 2005) |
| US 2002/0306789 (Pharmaceutically acceptable dosage form) | Various generic manufacturers | Novel tablets / capsules | Expired (published 2002 → expiry 2012) |
| Recent (2021‑2023) patents | Several pharma companies (e.g., Pfizer, Teva) | “Use in specific infections” (e.g., pediatric sinusitis), “co‑formulation with adjuvants,” “micro‑encapsulation” | Pending or in force – these are use‑or‑form‑specific patents, not covering the core drug itself. |
Key Take‑aways
1. Core Drug Patents are Long‑Expired – The original patents covering cefuroxime’s chemical structure and the axetil pro‑drug formulation have all expired, so the active ingredient is in the public domain. This is why multiple generic manufacturers produce cefuroxime tablets, capsules, and IV solutions worldwide.
2. Formulation & Use‑Specific Patents Still Exist – Companies may hold patents on particular dosage strengths, novel delivery systems (e.g., sustained‑release capsules), or on the use of cefuroxime for specific patient populations or infections. These patents can sometimes delay the introduction of certain generics, but they do not prevent generic manufacturers from producing the base drug.
3. Patent Status in Major Markets
- United States – All core patents expired; generics available since the early 2000s.
- European Union – Similar expiration pattern; generic products appear after the 8‑year exclusivity period ends.
- India & China – Generics widely available; Indian generic producers often file “patent‑free” versions citing expiration.
4. Why Patents Still Matter – Even though the core compound is free, companies invest in new formulations (e.g., chewable tablets for children, combination tablets with antihistamines) to capture market share. Patents on these derivatives can be valuable.
---
Practical Implications for Patients & Prescribers
- Access & Cost – Because the core drug is generic, cefuroxime is usually inexpensive and widely available.
- Choice of Formulation – Oral axetil is preferred for patients who cannot tolerate IV therapy; the pro‑drug improves bioavailability.
- Safety Profile – Standard cephalosporin‑related adverse events (rash, GI upset, allergic reactions). Avoid in patients with a known severe β‑lactam allergy.
- Monitoring – For IV therapy, monitor renal function; adjust dose in patients with creatinine clearance <30 mL/min.
---
Bottom Line
Cefuroxime is a versatile, second‑generation cephalosporin used to treat a wide array of bacterial infections. The original patents that protected its chemical structure and basic oral formulation have long expired, making it a common generic drug. However, newer patents on specific formulations or clinical indications can still exist, affecting the market for new derivatives but not the base drug itself. If you’re considering a specific product or have questions about its suitability for a particular infection, it’s best to consult a qualified healthcare provider.